ProPharma Group
ProPharma Group is recorded as a service provider in 66 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 66 trials · Latest update first
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
Sponsor Atea Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- A global amendment increased the planned eligible sample from 1500 to approximately 2510 because low global COVID-19 hospitalization and death rates reduced endpoint event rates.
- Rapid enrollment prevented the planned interim analysis after 65% of subjects completed Day 29 assessments; consequently, adolescent enrollment was not recommended and no pediatric subjects were enrolled.
- Of 218 screen failures, 177 were due to failure to meet entry criteria.
- Enrollment was concentrated in North America (1811/2285 subjects), whereas Europe enrolled 57 subjects, Asia 170 subjects, and other countries 247 subjects.
These findings describe the trial, not the service provider’s performance or responsibility.
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Mediar Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI1284 in Patients with Psychosis Associated with Alzheimer’s Disease
Sponsor Intra-Cellular Therapies Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of Navepegritide Administered Once Weekly for 52 Weeks in Adolescents (12-<18 Years of Age) with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Sponsor Grifols Therapeutics LLC
- Start (EU)
- Latest update
- Estimated end
J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia
Sponsor Ascendis Pharma Growth Disorders A/S
- Start (EU)
- Latest update
- Estimated end
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS Trial)
Sponsor Epygenix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sponsor Cellectis
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Sponsor Rayzebio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Sponsor Cellectis
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)
Sponsor Grifols Therapeutics LLC
- Start (EU)
- Latest update
- Estimated end
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ProPharma Group?
The 2026-10-09 snapshot links ProPharma Group to 66 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Regulatory services, Quality assurance & auditing, Clinical monitoring, among 25 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ProPharma Group?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Neurology, Immunology, Respiratory. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ProPharma Group conducted?
The linked trials record locations in 25 countries, including Spain, France, Italy, Germany, Netherlands. These are trial locations, not confirmed office locations or countries where ProPharma Group delivered services.
What can this page tell me about ProPharma Group's trial experience?
Browse 66 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 5 recorded name variants under ProPharma Group. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ProPharma Group GmbH
- Propharma Group
- Propharma Group LLC
- Propharma Group Mis Limited
- Propharma Group The Netherlands B.V.